Praxis Precision Medicines, Inc. held an Investor Day event on November 12, 2026, in New York City. The company provided an overview of its commercial strategy and launch plans for its two lead product candidates, relutrigine and ulixacaltamide, alongside updates regarding its expanded development pipeline.
Regarding ulixacaltamide, the company presented an updated population-based prevalence estimate for essential tremor in the United States, identifying approximately 9 million people, including about 2 million currently seeking treatment. Management shared sensitivity analyses of the Essential3 primary endpoint, which were consistent with the primary result. Additionally, an early analysis of patients in the Essential3 long-term safety study who completed efficacy assessments after approximately 95 weeks of treatment showed durable and improving activities of daily living (ADL) response.
For relutrigine, the company shared updated open label extension data from the EMBOLD study in SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEEs). The data indicated a continued reduction in seizures through 18 months, with an 86% reduction in seizures from baseline.
Praxis outlined a significant expansion of its pipeline for 2027. In the movement disorders franchise, the company plans to initiate studies with ulixacaltamide in Parkinson’s disease (approximately 1 million patient prevalence), restless legs syndrome (5 to 8 million patient prevalence), and autism spectrum disorder (8 million patient prevalence). The company also plans to advance two new molecular entities that optimize t-type calcium channel mechanisms, with the first in human studies expected in 2027. Furthermore, the company is collaborating with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide, which is planned to enter the clinic in 2027.
In the pain franchise, Praxis introduced a two-pronged approach utilizing a pan-sodium channel strategy and a NaV1.8 isoform biased strategy. The company is advancing PRAX-215, a pan-sodium channel molecule currently in a Phase 1 SAD/MAD study with a readout expected in 2027, and PRAX-110, an isoform biased molecule expected to enter the clinic in 2028.
Other pipeline updates included the introduction of PRAX-206 for KCNT1 developmental epilepsies, which has shown strong pre-clinical data and is planned to enter the clinic in early 2027. The company also shared a portfolio of six preclinical antisense oligonucleotide programs being advanced within the Solidus platform, in addition to elsunersen, which is in pivotal development.
